Kras status - PowerPoint PPT Presentation

Department of GI Medical Oncology

Cathy Eng, M.D., F.A.C.P. Associate Professor Associate Medical Director, Colorectal Center Director of Network Clinical Research, GI Med Onc March 28, 2014. Does the New EPOC trial eliminate Anti -EGFR antibodies as part of pre-op therapy for curable liver-only mCRC ? YES!.

★ ★ ★ ★ ★

626 views • 38 slides

Carsten Bokemeyer*

KRAS status and efficacy in the first-line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience. Carsten Bokemeyer* I Bondarenko, J Hartmann, F De Braud, C Volovat, C Stroh, J Nippgen, I Celik, P Koralewski.

★ ★ ★ ★ ★

355 views • 20 slides

$Age &gt;20 years Fluoropyrimidine, oxaliplatin, and irinotecan refractory ECOG PS 0–2$

Age &gt;20 years Fluoropyrimidine, oxaliplatin, and irinotecan refractory ECOG PS 0–2

Clinical outcome in patients with metastatic colorectal cancer harboring KRAS p.G13D mutation treated with Cetuximab GI-biomarker 0902. Enrollment: 94. SD. PD. PR.

★ ★ ★ ★ ★

154 views • 1 slides

View Kras status PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Kras status PowerPoint presentations. You can view or download Kras status presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.

Kras status - PowerPoint PPT Presentation

Department of GI Medical Oncology

Carsten Bokemeyer*

Age &amp;gt;20 years Fluoropyrimidine, oxaliplatin, and irinotecan refractory ECOG PS 0–2

Age >20 years Fluoropyrimidine, oxaliplatin, and irinotecan refractory ECOG PS 0–2